As China's aging population increases demand for therapies treating everything from cancer and diabetes to dementia, the ...

As its lead candidate advances into a late-stage trial for pulmonary arterial hypertension (PAH), Inhibikase Therapeutics has picked up a commercial leader with plenty of experience in the PAH space.

After an extended period of decline and subsequent consolidation, Pfizer's stock is attracting renewed interest following two ...